Legato Capital Management LLC cut its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 40.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,778 shares of the company's stock after selling 43,769 shares during the quarter. Legato Capital Management LLC owned about 0.10% of Evolus worth $715,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in EOLS. KBC Group NV acquired a new stake in shares of Evolus in the 4th quarter valued at $49,000. Point72 Asset Management L.P. bought a new position in Evolus during the third quarter valued at about $132,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after buying an additional 1,291 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Evolus in the third quarter worth about $191,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Evolus during the 3rd quarter worth about $212,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.
Evolus Stock Performance
NASDAQ:EOLS traded down $0.30 during mid-day trading on Monday, hitting $14.74. 792,881 shares of the company's stock traded hands, compared to its average volume of 871,879. The firm has a market capitalization of $933.34 million, a price-to-earnings ratio of -16.20 and a beta of 1.33. The firm has a 50 day moving average of $12.13 and a two-hundred day moving average of $14.00. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12 month low of $9.25 and a 12 month high of $17.82.
Analysts Set New Price Targets
A number of brokerages recently weighed in on EOLS. Barclays raised their price objective on Evolus from $20.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday, January 27th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Evolus in a research report on Tuesday, January 21st. Finally, HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Friday.
Check Out Our Latest Analysis on EOLS
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
